Neurogene director granted 7,700 stock options
Neurogene Inc. director Keith Woods received a fully vested stock option grant covering 7,700 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4/A
Rhea-AI Filing Summary
Neurogene Inc. director Keith Woods received a fully vested stock option grant covering 7,700 shares of common stock. The option has an exercise price of $42.59 per share and expires on June 14, 2034. Following this award, he holds 7,700 stock options directly.
Insider Trade Summary
Grant/Award: 7,700 shares
Grant/Award
1 txn
Insider
Woods Keith
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 7,700 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 7,700 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 7,700 contracts (Direct)
Footnotes (1)
- F1. This option is fully vested.
Key Figures
Options granted: 7,700 options
Exercise price: $42.59 per share
Total options after grant: 7,700 options
+2 more
5 metrics
Options granted
7,700 options
Director stock option grant on June 14, 2024
Exercise price
$42.59 per share
Stock option exercise price for 7,700 options
Total options after grant
7,700 options
Total derivative securities following transaction
Option expiration
June 14, 2034
Expiration date of granted stock options
Transaction code
A (grant/award acquisition)
Form 4/A transaction classification
Key Terms
Stock Option (Right to Buy), derivative, fully vested, Common Stock, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative financial
"transaction_type: "derivative" for the stock option grant"
A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.
fully vested financial
"footnote states: "This option is fully vested.""
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition regulatory
"transaction_code_description: "Grant, award, or other acquisition""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Neurogene Inc. (NGNE) report for Keith Woods?
Neurogene reported that director Keith Woods received a fully vested stock option grant for 7,700 shares of common stock. The award was recorded as a derivative acquisition on the Form 4/A, increasing his directly held stock options to 7,700.
What is the exercise price of Keith Woods’ new Neurogene (NGNE) stock options?
The granted stock options have an exercise price of $42.59 per share. This means Woods can purchase up to 7,700 Neurogene common shares at $42.59 each any time before the options expire on June 14, 2034.
How many Neurogene (NGNE) stock options does Keith Woods hold after this Form 4/A?
After the reported award, Keith Woods holds 7,700 stock options directly. The Form 4/A shows total derivative securities following the transaction at 7,700, matching the number of options granted in this filing.
When do Keith Woods’ newly granted Neurogene (NGNE) options expire?
The stock options granted to Keith Woods expire on June 14, 2034. He may choose to exercise up to 7,700 options at the fixed exercise price of $42.59 per share any time before that expiration date.
Are the Neurogene (NGNE) stock options granted to Keith Woods vested?
Yes, the filing states that this option grant is fully vested. Being fully vested means Woods has the right to exercise all 7,700 options at the exercise price of $42.59 per share immediately, subject to the option’s expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
